Open AccessRetreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria
Author(s) -
Martin Metz,
Tatevik Ohanyan,
Martin K. Church,
Marcus Maurer
Publication year - 2014
Publication title -
jama dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2013.8705
Subject(s) - omalizumab , medicine , discontinuation , dermatology , adverse effect , chronic urticaria , angioedema , immunoglobulin e , immunology , antibody
Omalizumab has emerged as a novel and effective treatment option for patients with antihistamine-resistant chronic urticaria. It is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab treatment can benefit from retreatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom